Fierce Pharma

MAY 24, 2024

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic

Patients 321

Patients 321

MedCity News

MAY 24, 2024

Allegheny Health Network rolled out a large language model designed exclusively for use by its staff members. You can think of the tool as the health system’s own version of Chat-GPT, said Ashis Barad, AHN’s chief digital and information officer. The post Why Allegheny Health Network Created Its Own Chat-GPT For Employees appeared first on MedCity News.

Networking 118

Networking Healthcare Healthcare 118

Fierce Pharma

MAY 24, 2024

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). | The FDA awarded the voucher based on Paxlovid's status as a countermeasure to a material medical threat, according to a notice in the Federal Register.

FDA 292

FDA Sales Medical 292

MedCity News

MAY 24, 2024

Tracey James, chief operating officer of Walgreens’ specialty pharmacy business, talked about the retailer’s vision of innovating in the specialty pharmacy world, as well as about affordability and access. The post MedCity Pivot Podcast: A Conversation With Walgreens’ Head of Specialty Drugs appeared first on MedCity News.

Retail 95

Retail Biopharma 95

Advertisement

Fierce Pharma

MAY 24, 2024

AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore. | AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore.

FDA 185

FDA Pharma 185

pharmaphorum

MAY 24, 2024

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy. The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), which will be reported at the ASCO congress next week.

Patients 94

Patients 94

Pharmaceutical Technology

MAY 24, 2024

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

FDA 98

FDA 98

MedCity News

MAY 24, 2024

Lyra Care for Teens will be available starting in June. Patients will gain access to therapists who specialize in evidence-based treatments and personalized digital lessons. The post Lyra Health Announces Mental Health Offering for Teens appeared first on MedCity News.

Specialization 89

Specialization Patients 89

pharmaphorum

MAY 24, 2024

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine figures and smaller rounds for Progentos, LabGenius, and Grey Wolf, and Imvax.

85

85

PharmaTech

MAY 24, 2024

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

Manufacturing 96

Manufacturing 96

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmaTimes

MAY 24, 2024

The lifelong autoimmune disease affects more than 150,000 people living in the UK

Doctors 109

Doctors Training Management 109

pharmaphorum

MAY 24, 2024

NICE and NHS England are seeking feedback on proposed new rules and commissioning principles for medtech products.

88

88

MedCity News

MAY 24, 2024

Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro. The post Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro appeared first on MedCity News.

Manufacturing 66

Manufacturing Pharmaceutical Biopharma Pharma 66

pharmaphorum

MAY 24, 2024

Shares in Merus spike on ASCO abstract on phase 2 trial of EGFRxLGR5 bispecific petosemtamab in head and neck cancer.

85

85

Advertisement

Distribution

PharmaTimes

MAY 24, 2024

The conference will take place on 23 to 24 October at Vienna AirportCity

Pharmaceutical 96

Pharmaceutical 96

Pharmaceutical Technology

MAY 24, 2024

Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.

72

72

Penrod

MAY 24, 2024

1. Inefficient Appointment Scheduling An inefficient appointment scheduling system can lead to long wait times, double booking, and limited appointment availability, frustrating your existing and potential patients. These issues can disrupt the flow of your practice, causing dissatisfaction and potentially leading to a loss of patients. To solve this problem, you need a comprehensive booking system that offers consistency at each intake location.

Healthcare Provider 52

Healthcare Provider Healthcare Healthcare Patients 52

Scott Burrows

MAY 24, 2024

A few weeks ago, I had the incredible opportunity to tee off at the prestigious Medalist Golf Club in Jupiter, Florida. As I made my way down the manicured fairways and navigated the challenging greens, I couldn’t help but feel a sense of awe knowing that I was playing on the same course frequented by golf legends like Tiger Woods and Rory McIlroy.

Specialization 52

Specialization Media 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmaTimes

MAY 24, 2024

JHU083 reduced tumour growth and triggered tumour cell death in mice

82

82

PharmaTech

MAY 24, 2024

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Leads 52

Leads 52

Pharmaceutical Technology

MAY 24, 2024

The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.

59

59

PharmExec

MAY 24, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Pharmaceutical Technology

MAY 24, 2024

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.

Safety 59

Safety 59

PharmExec

MAY 24, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Healthcare 52

Healthcare Healthcare 52

Pharmaceutical Technology

MAY 24, 2024

Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation technology.

52

52

PharmExec

MAY 24, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Patients 52

Patients Pharma 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Commerce

MAY 24, 2024

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

Manufacturing 52

Manufacturing 52

Pharmaceutical Technology

MAY 24, 2024

Affecting more than 162,000 patients worldwide, global clinical trials are researching innovative new treatments for cystic fibrosis.

Patients 52

Patients 52

Pharmacy Times

MAY 24, 2024

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.

Patients 57

Patients 57

Pharmaceutical Technology

MAY 24, 2024

MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.

52

52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization